Literature DB >> 23153444

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.

Christine A Shaw1, Jean-Rene Galarneau, Kathryn E Bowenkamp, Kurt A Swanson, Gene A Palmer, Giuseppe Palladino, Judit E Markovits, Nicholas M Valiante, Philip R Dormitzer, Gillis R Otten.   

Abstract

In the 1960s, infant immunization with a formalin-inactivated respiratory syncytial virus (FI-RSV) vaccine candidate caused enhanced respiratory disease (ERD) following natural RSV infection. Because of this tragedy, intensive effort has been made to understand the root causes of how the FI-RSV vaccine induced a pathogenic response to subsequent RSV infection in vaccinees. A well-established cotton rat model of FI-RSV vaccine-enhanced disease has been used by numerous researchers to study the mechanisms of ERD. Here, we have dissected the model and found it to have significant limitations for understanding FI-RSV ERD. This view is shaped by our finding that a major driver of lung pathology is cell-culture contaminants, although FI-RSV immunization and RSV challenge serve as co-factors to exacerbate disease. Specifically, non-viral products from the vaccine and challenge preparations that are devoid of RSV give rise to alveolitis, which is considered a hallmark of FI-RSV ERD in the cotton rat model. Although FI-RSV immunization and RSV challenge promote more severe alveolitis, they also drive stronger cellular immune responses to non-viral antigens. The severity of alveolitis is associated with T cells specific for non-viral antigens more than with T cells specific for RSV. These results highlight the limitations of the cotton rat ERD model and the need for an improved animal model to evaluate the safety of RSV vaccine candidates.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153444     DOI: 10.1016/j.vaccine.2012.11.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.

Authors:  Hye Suk Hwang; Young-Man Kwon; Jong Seok Lee; Si-Eun Yoo; Yu-Na Lee; Eun-Ju Ko; Min-Chul Kim; Min-Kyoung Cho; Young-Tae Lee; Yu-Jin Jung; Ji-Yun Lee; Jian-Dong Li; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

2.  Characterization of Cotton Rat (Sigmodon hispidus) Eosinophils, Including Their Response to Respiratory Syncytial Virus Infection.

Authors:  M Gia Green; Natasha Petroff; Krista M D La Perle; Stefan Niewiesk
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

3.  A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Authors:  Dai Wang; Shannon Phan; Daniel J DiStefano; Michael P Citron; Cheryl L Callahan; Lani Indrawati; Sheri A Dubey; Gwendolyn J Heidecker; Dhanasekaran Govindarajan; Xiaoping Liang; Biao He; Amy S Espeseth
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

4.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

5.  Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.

Authors:  Jong Seok Lee; Min Kyoung Cho; Hye Suk Hwang; Eun-Ju Ko; Yu-Na Lee; Young-Man Kwon; Min-Chul Kim; Ki-Hye Kim; Young-Tae Lee; Yu-Jin Jung; Sang-Moo Kang
Journal:  J Interferon Cytokine Res       Date:  2014-07-22       Impact factor: 2.607

6.  Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.

Authors:  Jessica J O'Konek; Paul E Makidon; Jeffrey J Landers; Zhengyi Cao; Carrie-Anne Malinczak; Jessie Pannu; Jennifer Sun; Vira Bitko; Susan Ciotti; Tarek Hamouda; Zbigniew W Wojcinski; Nicholas W Lukacs; Ali Fattom; James R Baker
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.

Authors:  Miaoge Xue; Rongzhang Wang; Olivia Harder; Phylip Chen; Mijia Lu; Hui Cai; Anzhong Li; Xueya Liang; Ryan Jennings; Krista La Perle; Stefan Niewiesk; Mark E Peeples; Jianrong Li
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 8.  Current concepts and progress in RSV vaccine development.

Authors:  Aleks K Guvenel; Christopher Chiu; Peter Jm Openshaw
Journal:  Expert Rev Vaccines       Date:  2014-01-09       Impact factor: 5.683

9.  Effects of formalin-inactivated respiratory syncytial virus (FI-RSV) in the perinatal lamb model of RSV.

Authors:  Rachel J Derscheid; Jack M Gallup; Cory J Knudson; Steven M Varga; Drew D Grosz; Albert van Geelen; Shannon J Hostetter; Mark R Ackermann
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

10.  Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats.

Authors:  Yoshiaki Yamaji; Yosuke Yasui; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.